The NeurologyLive® multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related disorders such as neuromyelitis optica spectrum disorder.
Check out some of NeurologyLive®'s featured content in the carousel below.
Institutional Perspectives in Neurology, Chaired by Robert T. Naismith, MD
November 10th 2022Chaired by Robert T. Naismith, MD, of Washington University in St. Louis, the presentations also feature Salim Chahin, MD, MSCE; Anne H. Cross, MD; Gregory F. Wu, MD, PhD; and Matthew R. Brier, MD, PhD. [WATCH TIME: 1 hour, 55 minutes]
Advocacy and Empowerment: Finding Your Advocacy Community
November 9th 2022The Palatucci Advocacy Leadership Forum, or PALF, sponsored by the American Academy of Neurology, gives neurologists and trainees tools to successfully advocate for their ideas and develop their identity as physician advocates.
Telehealth and Digital Measures May Assist With Monitoring MS Progression: Marisa McGinley, DO
November 7th 2022The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke about her presentation from ECTRIMS 2022 on teleneurology and its utilization as a tool to make care more accessible to patients with MS. [WATCH TIME: 7 minutes]
Advocacy in Neurology: A Tool to Serve and Find Fulfillment
November 7th 2022Acting as an advocate is meaningful to neurologists because it speaks to their inner core—or their “why.” Neurologists have the agency to make this world a better place while working as a neurologist and an advocate at many levels.
Teleneurology Overcomes Health Disparities and Improves Accessibility in MS: Marisa McGinley, DO
November 6th 2022The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke about her presentation on teleneurology being a beneficial healthcare tool for patients with MS at ECTRIMS 2022. [WATCH TIME: 7 minutes]
Critical Aspects of Treatment During Postpartum in Patients with MS, NMOSD: Riley Bove, MD
November 3rd 2022The associate professor of neurology at the University of California, San Francisco, discussed the key points from an oral presentation at ECTRIMS 2022 on understanding postpartum for patients with MS and NMOSD. [WATCH TIME: 4 minutes]
Emerging Biomarkers to Consider for NMOSD, Neuromyeltis Optica: Bruce Cree, MD, PhD, MAS, FAAN
November 3rd 2022The clinical research director of the UCSF Multiple Sclerosis Center discussed the need for measures of progression in neuromyelitis optica and the next steps in treatment. [WATCH TIME: 4 minutes]
Positive Safety Profile of Anti-CD20 Therapy During Postpartum in MS, NMOSD: Riley Bove, MD
November 2nd 2022The associate professor of neurology at the University of California, San Francisco, discussed takeaways from an oral presentation at ECTRIMS 2022 on the use of anti-CD20 therapies in postpartum for patients with MS and NMOSD. [WATCH TIME: 5 minutes]
Ocrelizumab’s Impact on Humoral Response to EBV: Robert Zivadinov, MD, PhD
November 1st 2022The director of the Buffalo Neuroimaging Analysis Center provided context on a new study exploring ocrezliumab’s (Ocrevus; Genentech) effect on leptomeningeal inflammation and humoral response to EBV. [WATCH TIME: 5 minutes]
Capabilities of Stem Cell Transplantation vs Other Relapsing MS Therapies: Tomas Kalincik, MD, PhD
November 1st 2022The professor of neurology and biostatistician at University of Melbourne and Royal Melbourne Hospital spoke on stem cell transplantation in patients with MS and its effectiveness in comparison with other traditional approaches. [WATCH TIME: 2 minutes]
Paleolithic and Mediterranean Diets Show Greatest Impact on QoL, Fatigue in Multiple Sclerosis
November 1st 2022In the meta-analysis, the Paleolithic and Mediterranean diets continued to outperform other dietary interventions such as ketogenic, anti-inflammatory, fasting, and calorie restriction on fatigue and quality-of-life outcomes.
Therapeutic Focuses of MS and the Need to Reach NEDA Status: Stuart Silverman, MD
October 31st 2022As the treatment landscape for relapsing MS continues to strengthen, the neurologist at Allegheny Health Network discussed the reasons for continued pursuit of drug development. [WATCH TIME: 3 minutes]
Early Intervention of Highly-Effective DMTs Results in Higher Probability of Achieving NEDA-3
October 30th 2022Among those on early highly-effective treatments, shorter disease duration and shorter time between first treatment and current treatment led to more patients achieving no evidence of disease activity.